Complications of HIV Disease and Antiretroviral Therapy
ABSTRACT As antiretroviral treatment regimens become more potent and easier to administer, differences in the rates of adverse events and complications associated with treatment will increasingly drive decisions regarding the selection of therapy. This year's Conference on Retroviruses and Opportunistic Infections featured a wide range of research directed toward understanding the pathogenesis, treatment, and long-term consequences of complications associated with HIV infection and the use of antiretroviral therapy in both resource-limited settings and in the developed world. This review will summarize information on complications of antiretroviral therapy in resource-limited settings, hepatitis C virus, tuberculosis, and discussion of metabolic, cardiovascular, and renal complications.
- SourceAvailable from: Mary Duro
[Show abstract] [Hide abstract]
- "There are many works in the literature presenting a wide range of values for lipodystrophy. Between 3% and 64% was referred by Carr in 1998 , Lichtenstein in 2003  and Currier in 2005 , values of 20%, 30% to 50% by Behrens in 2006  and 48.7% according to Bogner et al. in 2001 . The very different Clinical Biochemistry 46 (2013) 740–744 ⁎ Corresponding author. "
ABSTRACT: OBJECTIVE: Study of the lipid profile in patients infected with HIV treated with different combinations of High Activity Anti-Retroviral Therapy (HAART). Design and Methods A retrospective cohort study of the lipid profile in patients undergoing HAART. The study analyses the evolution of concentrations of triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDLc) and HDL-cholesterol (HDLc) in a period of at least three years of treatment. From a total of 750 clinical cases analysed in Hospital Joaquim Urbano (Oporto, Portugal) 124 patients were selected for this study. RESULTS: After three years of treatment, we observed the development of dyslipidaemia by increases in TG (17%), TC (29%) and LDLc (9%), particularly in patients treated with a combination of drugs which included protease inhibitors (PI). Moreover, the Non-Nucleoside-Inhibitors of Reverse Transcriptase (NNRTI) were associated with better lipid profile. The increase of 46% in HDLc was the most surprising finding. CONCLUSIONS: he results indicate that patients with HAART have a more atherogenic lipidic profile with increased TC, LDLc and TG levels. Since the effectiveness of NNRTI is similar to that of PI, but with a smaller atherogenic profile, it should be the first choice drug to be selected in the HIV treatment.Clinical biochemistry 01/2013; 46(9). DOI:10.1016/j.clinbiochem.2012.12.017 · 2.28 Impact Factor
[Show abstract] [Hide abstract]
- "With effective treatment, HIV infection can be considered to be a chronic condition (Palella et al., 1998, 2003). However, current anti-retroviral treatments can have major adverse effects (Currier & Havlir, 2005). Thus, functioning and well-being are important to consider when evaluating therapy, and when treating patients with HIV (Wu, 2000). "
ABSTRACT: DYNHA SF-36 is a computerized adaptive test version of the SF-36 Health Survey. The feasibility of administering a modified DYNHA SF-36 to adults with HIV was evaluated with Johns Hopkins University Moore (HIV) Clinic patients (N=100) and Internet consumer health panel members (N=101). Participants completed the DYNHA SF-36, modified to capture seven health domains [(physical function (PF), role function (RF, without physical or emotional attribution), bodily pain (BP), general health, vitality (VT), social function (SF), mental health (MH)], and scored to produce two summary components [Physical Component Summary (PCS), Mental Component Summary (MCS)]. Item-response theory-based response consistency, precision, mean scores, and discriminant validity were examined. A higher percentage of Internet participants responded consistently to the DYNHA SF-36. For each domain, three standard deviations were covered with five items (90% reliability); however, RF and SF scores were less precise at the upper end of measurement (better functioning). Mean scores were slightly higher for the Internet sample, with the exception of VT and MCS. Clinic and Internet participants reporting an AIDS diagnosis had significantly lower mean PCS and PF scores than those without a diagnosis. Additionally, significantly lower RF and BP scores were found for Internet participants reporting an AIDS diagnosis. The measure was well accepted by the majority of participants, although Internet respondents provided lower ratings for the tool's usefulness. The DYNHA SF-36 has promise for measuring the impact of HIV and its treatment in both the clinic setting and through telemonitoring.AIDS Care 07/2012; DOI:10.1080/09540121.2012.656573 · 1.60 Impact Factor